Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer Patients

PRIMARY OBJECTIVE: Evaluation of complete response rate on treatment combining FOLFIRINOX and panitumumab SECONDARY OBJECTIVE(S): * Overall Survival * Progression free survival * Secondary resection * Early tumor shrinkage (ETS) * Depth of response (DpR) * Safety profile (NCI-CTCAE v4.03 classification) * Diagnostic performance of ccfDNA analysis compared to the tumor-tissue analysis (current gold standard)